--- title: "China approved a brain chip for sale before Neuralink could. Here is the real gap." date: 2026-09-20 category: Brain–Computer Interface site: NeuroAI canonical: https://neuroai.site/a/na-bci-neuralink-china-compare language: en --- # China approved a brain chip for sale before Neuralink could. Here is the real gap. > Neuralink had implanted roughly two dozen people by mid-2026 but still had no commercial approval; China's NEO became the first approved implantable brain-computer interface in March 2026. A paralysed man in Shanghai picked up a cup using only his thoughts, then later wrote his own name without the device at all. A paralysed man in Texas moved a cursor with his mind and played chess online. Same dream, two very different regulatory endings. ## The two programs, side by side **Neuralink** put its first implant in a person in January 2024. By 30 June 2026 the company had roughly **26 participants** enrolled globally in its trials, up from 21 at the start of the year, according to disclosures reflected in a US SEC filing and corroborated by multiple outlets. The implant, called N1, is about 23 mm across and carries **1,024 electrodes** on 64 ultrathin threads placed in the motor cortex by a surgical robot. Trials run in the US, the UK (seven patients via GB-PRIME at University College London Hospital), Canada and the UAE. **China's NEO** (Neural Electronic Opportunity) was approved by the National Medical Products Administration (NMPA) on **13 March 2026** as the world's first approved implantable brain-computer interface (脑机接口) Class III medical device, confirmed by Xinhua and People's Daily. It was developed by Neuracle Technology (Shanghai) Co., Ltd. (博睿康) and tested under a multicentre trial led by Huashan Hospital (Fudan University) across **11 hospitals with 32 cases**, where hand-grasp function improved in **100%** of patients. ## The gap that actually matters The headline gap is regulatory. Neuralink remains an investigational device in the United States with **no FDA premarket approval** as of 2026. China granted NEO a marketing licence and, by July 2026, performed its first commercial implant surgery at Huashan. Shanghai has since brought the system onto medical insurance — meaning a Chinese patient can, in principle, be treated and reimbursed today, while an American patient can only join a study. That is not a verdict on which technology is better. It is a verdict on which system moved a device from lab to licence first. ## The technical divergence nobody mentions The two implants are not the same kind of invasive. - **Neuralink** uses **intracortical** threads pushed into the brain tissue — higher resolution, higher surgical risk. - **NEO** uses an **epidural** approach, sitting on the brain's surface, trading some signal richness for lower tissue damage. Different trade-offs. Neuralink's 1,000-plus electrodes suggest finer control; NEO's epidural placement is explicitly designed to avoid direct brain injury. Neither has published long-term decay data — both need five to ten years of follow-up before anyone can claim durability. ## Three cold showers - **Approved is not cured.** NEO is a "hand motor function compensation system." It routes around the injury; it does not repair the severed nerve. Some patients showed signs of neural remodelling after training, but the mechanism is not yet understood. - **The populations are narrow.** Both target specific, severe conditions — quadriplegia from cervical spinal cord injury, or ALS. Tens of patients, not tens of thousands. - **It is still surgery.** Infection, stability and signal decay over time are open questions for every implantable brain-computer interface (脑机接口). ## What "approved" actually unlocks An approval number sounds bureaucratic, but it changes three things a trial cannot. First, a doctor can prescribe the device rather than recruit a subject — the difference between a treatment and an experiment. Second, hospitals can budget for it, and in Shanghai's case insurers can reimburse it, opening a path most Western BCI patients do not yet have. Third, the manufacturer can sell, service and improve it as a product, not a research line item. None of this means NEO is finished; only that it crossed the line Neuralink has not, from study to shelf. ## What this means if you or a family member is affected - **Check approval and reimbursement before hope.** "Approved" and "covered" are different doors; China's NEO has walked through both, Neuralink through neither. - **Match the device to the diagnosis.** These are not general-purpose brain upgrades; each has strict indications. - **Be wary of consumer "BCI" gadgets.** Headbands and focus trainers are not the same as a regulated implantable brain-computer interface (脑机接口). The race is not about who implanted first. It is about who turned an implant into a product a doctor can prescribe. ## Honest limitations Neuralink's count (about 26 as of 30 June 2026) is drawn from the company's own disclosures as reflected in a US SEC filing and secondary reporting; we could not independently audit the enrolment and present it as company-reported. NEO's approval date, 32-case trial and 100% grasp-improvement rate come from Xinhua, People's Daily and Fudan University's Huashan Hospital — primary or near-primary Chinese sources; we did not access the NMPA registration dossier directly. "World's first approved implantable BCI" reflects China's NMPA claim and Xinhua wording; no comparable FDA approval existed as of 2026, but other jurisdictions may use different device definitions. No public RMB price for NEO was available; Shanghai insurance coverage is reported but the reimbursement amount is not stated here, so no currency conversion is given. --- Published by NeuroAI (https://neuroai.site/) — https://neuroai.site/a/na-bci-neuralink-china-compare Free to quote with attribution and a link to the original.